Маркеры множественной лекарственной устойчивости при острых миелоидных лейкозах
https://doi.org/10.17650/1818-8346-2006-0-1-2-9-15
Об авторах
О. Д. ЗахаровРоссия
Москва
Е. Ю. Рыбалкина
Россия
Москва
М. А. Волкова
Россия
Москва
А. А. Ставровская
Россия
Москва
Список литературы
1. Савченко В.Г., Паровичникова Е.Н. Лечение острых лейкозов. М., 2004.
2. Ставровская А.А. Резистентность больных гемобластозами к лекарственной терапии. В кн.: Клиническая онкогематология. Под ред. М.А. Волковой. М., Медицина; 2001.
3. Gregory D.L., Tito F., Susan E.B. The role of ABC transporters in clinical practice. The Oncologist 2003; 8(5):411—24.
4. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11(7):1156—66.
5. Riordan J.R., Ling V. Purification of Pglycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 1979;254(24):12701—5.
6. Guerci A., Merlin J.L., Missoum N. et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995;85: 2147—53.
7. van der Kolk D.M., de Vries E.G., van Putten W.J. et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 2000;6:3205—14.
8. Marie J.P., Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 1999;457:1—9.
9. Leith C.P., Kopecky K.J., I-Ming Chen et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group Study. Blood 1999;94(3): 1086—99.
10. Benderra Z., Faussat A.M., Sayadaye L. et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005;11:7764—72.
11. van Stijn A., van der Pol M.A., Kok A. et al. Differences between the CD34+ and CD34blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 2003;88(5):497—508.
12. Legrand O., Zompi S., Perrot J.Y. et al. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups. Haematologica 2004;89(1):34—41.
13. Damiani D., Tiribelli M., Calistri E. et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006;91:825—8.
14. Hunter H.M., Pallis M., Seedhouse C.H. et al. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. Br J Hemat 2004;127(1):26—33.
15. Cole S.P., Bhardwaj G., Gerlach J.H. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258(5088):1650—4.
16. Zhou D.C., Zittoun R., Marie J.P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia. 1995;9(10):1661—6.
17. Filipits M., Stranzl T., Pohl G. et al. MRP expression in acute myeloid leukemia. An update. Adv Exp Med Biol 1999;457:141—50.
18. Schaich M., Soucek S., Thiede Ch. et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Hemat 2005;128(3):324—32.
19. Kuss B.J., Deeley R.G., Cole S.P. et al. The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Leuk Lymphoma 1996;20(5—6):357—64.
20. Doyle L.A., Yang W., Abruzzo L.V. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci 1998;95:15665—70.
21. Benderra Z., Faussat A.-M., Sayada L. et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10:7896—902.
22. Abbott B.L., Colapietro A.-M., Barnes Y. et al. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002;100(13):4594—601.
23. List A.F., Spier C.S., Grogan T.M. et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996;87(6):2464—9.
24. Pirker R., Pohl G., Stranzl T. et al. The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia. Adv Exp Med Biol 1999;457:133—9.
25. Filipits M., Pohl G., Stranzl Th. et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998;91(5): 1508—13.
26. Huh H.J., Park C.J., Jang S. et al. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 2006;21(2):253—8.
Рецензия
Для цитирования:
Захаров О.Д., Рыбалкина Е.Ю., Волкова М.А., Ставровская А.А. Маркеры множественной лекарственной устойчивости при острых миелоидных лейкозах. Онкогематология. 2006;(1-2):9-15. https://doi.org/10.17650/1818-8346-2006-0-1-2-9-15
For citation:
Zakharov O.D., Rybalkina Ye.Yu., Volkova M.A., Stavrovskaya A.A. Multidrug resistance markers in acute myeloid leukemias. Oncohematology. 2006;(1-2):9-15. (In Russ.) https://doi.org/10.17650/1818-8346-2006-0-1-2-9-15